[en] The emergence of antimicrobial resistance renewed the interest in bacteriophages as complementary interventions to the use of antibiotics in veterinary medicine. The IABS workshop entitled "Avoiding Antimicrobial Resistance: Veterinary Use of Phages for Prevention, Therapy and Control of Bacterial Infections" brought together experts to discuss the scientific, regulatory and commercial challenges involved in bringing phage-based products to market. The biological characteristics of phages require innovative approaches for product development and regulatory approval. Dependent on their actual use, phages could be marketed as veterinary medicinal products, magistral preparations, food additives, or biocides, each classification implying different regulatory requirements and challenges, and none of which were originally intended for phage-based products. The meeting highlighted the need for regulatory harmonization to facilitate market access and allow manufacturers to choose the most appropriate regulatory pathway for their products. Recent EMA and EDQM guidelines offer some flexibility to take into account the biological nature of phages, but concerns remain about the feasibility of manufacturing phage-based products following existing rules for veterinary chemotherapeutants at commercially viable costs. Overcoming these regulatory and financial barriers is essential for the integration of phage therapy as a therapeutic option for control of bacterial infection and disease in veterinary medicine.
Disciplines :
Veterinary medicine & animal health
Author, co-author :
Antoine, Céline ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire
Mackay, David ; International Alliance for Biological Standardization (IABS-EU), 24 Rue Baldassini, Lyon, 69007, France
Midtlyng, Paul; International Alliance for Biological Standardization (IABS-EU), 24 Rue Baldassini, Lyon, 69007, France, Acadamic AS, 0454, Oslo, Norway
Kleppen, Hans P; Microphix AS, 0481, Oslo, Norway
Palić, Dušan ; International Alliance for Biological Standardization (IABS-EU), 24 Rue Baldassini, Lyon, 69007, France, Faculty of Veterinary Medicine, Ludwig-Maximilian University Munich, Munich, Germany
Pirnay, Jean-Paul; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Bruynstraat 1, 1120, Brussels, Belgium
Thiry, Damien ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires (DMI) > Bactériologie vétérinaire et maladies bactériennes animales
Thiry, Etienne ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires (DMI)
Language :
English
Title :
Bacteriophage-based veterinary products: aligning regulatory framework and development challenges for market integration.
Regulation - 2019/6 - EN - EUR-Lex n.d. https://eur-lex.europa.eu/eli/reg/2019/6/oj/eng (accessed March 10, 2025).
EMA. Guideline on quality, safety and efficacy of veterinary medicinal products specifically designed for phage therapy n.d. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-safety-and-efficacy-veterinary-medicinal-products-specifically-designed-phage-therapy_en.pdf. (Accessed 10 March 2025)
European Pharmacopoeia. General Chapter 5.31. Phage therapy medicinal products n.d. https://www.edqm.eu/documents/52006/277566/European%20Pharmacopoeia%20-%20Phage%20therapy%20medicinal%20products%20%285.31%29.pdf/d9da2e01-e002-32c9-b2eb-8a9360439c05?t=1727862827906. (Accessed 10 March 2025)
Memorandum of understanding between CVB and FDA | animal and plant health inspection service n.d. https://www.aphis.usda.gov/veterinary-biologics/regulations-guidance/mou-cvb-fda. (Accessed 10 March 2025)
Mo, J., Kleppen, H., Frantzen, C., Bårdsen, E., Gillund, B., Bruk av bakteriofagproduktet Custus®YRS til smittepresskontroll og sykdomsforebygging hos atlantisk laks. Nor Vet Tidskr 135 (2023), 150–157.
Avoiding Antimicrobial Resistance: Veterinary Use of Phages for Prevention. Therapy and control of bacterial infections – abstract book. Virtual meeting: international alliance for biological standardization (IABS). 2024.
Hazards BIOHAZ, Ep on, B., Koutsoumanis, K., Allende, A., Alvarez-Ordóñez, A., Bolton, D., Bover-Cid, S., et al. Update and review of control options for Campylobacter in broilers at primary production. EFSA J, 18, 2020, e06090, 10.2903/j.efsa.2020.6090.
Chinivasagam, H.N., Estella, W., Maddock, L., Mayer, D.G., Weyand, C., Connerton, P.L., et al. Bacteriophages to control Campylobacter in commercially farmed broiler chickens, in Australia. Front Microbiol, 11, 2020, 10.3389/fmicb.2020.00632.
D'Angelantonio, D., Scattolini, S., Boni, A., Neri, D., Di Serafino, G., Connerton, P., et al. Bacteriophage therapy to reduce colonization of Campylobacter jejuni in broiler chickens before slaughter. Viruses, 13, 2021, 1428, 10.3390/v13081428.
Atterbury, R.J., Connerton, P.L., Dodd, C.E.R., Rees, C.E.D., Connerton, I.F., Application of host-specific bacteriophages to the surface of chicken skin leads to a reduction in recovery of Campylobacter jejuni. Appl Environ Microbiol 69 (2003), 6302–6306, 10.1128/AEM.69.10.6302-6306.2003.
Smith, H.W., Huggins, M.B., Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 129 (1983), 2659–2675, 10.1099/00221287-129-8-2659.
Lee, C.Y., Kim, S.J., Park, B.C., Han, J.H., Effects of dietary supplementation of bacteriophages against enterotoxigenic Escherichia coli (ETEC) K88 on clinical symptoms of post-weaning pigs challenged with the ETEC pathogen. J Anim Physiol Anim Nutr 101 (2017), 88–95, 10.1111/jpn.12513.
Wall, S.K., Zhang, J., Rostagno, M.H., Ebner, P.D., Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Appl Environ Microbiol 76 (2010), 48–53, 10.1128/AEM.00785-09.
Volpi, M., Gambino, M., Kirkeby, K., Elsser-Gravesen, A., Brøndsted, L., Full-scale industrial phage trial targeting Salmonella on pork carcasses. Food Microbiol, 112, 2023, 104240, 10.1016/j.fm.2023.104240.
Nale, J.Y., McEwan, N.R., Bacteriophage therapy to control bovine mastitis: a review. Antibiotics, 12, 2023, 1307, 10.3390/antibiotics12081307.
Pirnay, J.-P., Verbeken, G., Magistral phage preparations: is this the model for everyone?. Clin Infect Dis 77 (2023), S360–S369, 10.1093/cid/ciad481.
Pirnay, J.-P., Djebara, S., Steurs, G., Griselain, J., Cochez, C., De Soir, S., et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol 9 (2024), 1434–1453, 10.1038/s41564-024-01705-x.
Onsea, J., Uyttebroek, S., Chen, B., Wagemans, J., Lood, C., Van Gerven, L., et al. Bacteriophage therapy for difficult-to-treat infections: the implementation of a multidisciplinary phage Task Force (the PHAGEFORCE study protocol). Viruses, 13, 2021, 1543, 10.3390/v13081543.
Hawkins, C., Harper, D., Burch, D., Änggård, E., Soothill, J., Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol, 2010, 10.1016/j.vetmic.2010.05.014.
Balcão, V.M., Belline, B.G., Silva, E.C., Almeida, P.F.F.B., Baldo, D.Â., Amorim, L.R.P., et al. Isolation and molecular characterization of two novel lytic bacteriophages for the biocontrol of Escherichia coli in uterine infections: in vitro and ex vivo preliminary studies in veterinary medicine. Pharmaceutics, 14, 2022, 2344, 10.3390/pharmaceutics14112344.
Marshall, K., Marsella, R., Topical bacteriophage therapy for staphylococcal superficial pyoderma in horses: a double-blind, placebo-controlled pilot study. Pathogens, 12, 2023, 828, 10.3390/pathogens12060828.
Braunstein, R., Hubanic, G., Yerushalmy, O., Oren-Alkalay, S., Rimon, A., Coppenhagen-Glazer, S., et al. Successful phage-antibiotic therapy of P. aeruginosa implant-associated infection in a Siamese cat. Vet Q 44 (2024), 1–9, 10.1080/01652176.2024.2350661.
Regulation - 1831/2003 - EN - EUR-Lex n.d. https://eur-lex.europa.eu/eli/reg/2003/1831/oj/eng (accessed March 11, 2025).
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Bampidis, V., Azimonti, G., Bastos, M. de L., Christensen, H., Dusemund, B., et al. Safety and efficacy of a feed additive consisting of the bacteriophages PCM F/00069, PCM F/00070, PCM F/00071 and PCM F/00097 (Bafasal®) for all avian species (Proteon Pharmaceuticals S.A.). EFSA J, 21, 2023, e07861, 10.2903/j.efsa.2023.7861.
Antoine, C., Laforêt, F., Fall, A., Blasdel, B., Delcenserie, V., Thiry, D., K1 capsule-dependent phage-driven evolution in Escherichia coli leading to phage resistance and biofilm production. J Appl Microbiol, 135, 2024, lxae109, 10.1093/jambio/lxae109.
